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Abstract
Monoclonal antibodies constitute one of the most important strategies to treat patients suf-
fering from cancers such as hematological malignancies and solid tumors. In order to guarantee
the quality of those preparations prepared at hospital, quality control has to be developed. The
aim of this study was to explore a noninvasive, nondestructive, and rapid analytical method to
ensure the quality of the final preparation without causing any delay in the process. We analyzed
four mAbs (Inlfiximab, Bevacizumab, Ramucirumab and Rituximab) diluted at therapeutic con-
centration in chloride sodium 0.9% using Raman spectroscopy. To reduce the prediction errors
obtained with traditional chemometric data analysis, we explored a data-driven approach using
statistical machine learning methods where preprocessing and predictive models are jointly opti-
mized. We prepared a data analytics workflow and submitted the problem to a collaborative data
challenge platform called Rapid Analytics and Model Prototyping (RAMP). This allowed to use
solutions from about 500 data scientists during five days of collaborative work. The prediction
of the four mAbs samples was considerably improved with a misclassification rate and the mean
error rate of 0.8% and 4%, respectively.
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1 Introduction
Cancer can be treated using numerous strategies, such as surgery, radiation therapy, immunother-
apy, hormone therapy, stem cell transplant, chemotherapy, and, recently, targeted therapy. Tar-
geted therapy, for example, using monoclonal antibodies (mAbs), is the foundation of precision
medicine. At present, it constitutes one of the most important strategies to treat patients suffer-
ing from cancers such as hematological malignancies and solid tumors. Monoclonal antibodies
are proteins which bind to specific substance on cancer cells and act by immune-mediated cell
killing mechanisms. They may therefore help the immune system to destroy cancer cells, stop
cancer cells from growing, stop signals that help to form blood vessels, deliver cell-killing sub-
stances to cancer cells, and cause cancer cell death. As classic chemotherapy drugs, mAbs are
commonly used alone or with other cytotoxic drugs or radioactive substances to kill cancer cells.
Those drugs designed for parenteral administration are aseptically prepared by pharmacists.
Drugs are extemporarily reconstituted or diluted in 5% glucose or 0.9% sodium chloride to obtain
a sterile final preparation at the dose prescribed by the physician. Even if pharmaceutical regula-
tion does not require final characterization of each compounding drugs, numerous pharmacists
have nevertheless implemented analytical control. Those controls have to be discriminant to en-
sure the nature of the drug in spite of similar physicochemical and spectral properties, sensitive to
guarantee the dose even for low concentrations and fast to secure the medication process without
delayed drug delivery. Consequently, different analytical strategies using direct flow injection
analysis, high performance liquid chromatography with UV detection [Delmas et al., 2009], or
vibrational molecular spectroscopies such as Raman and infrared caudron [Leˆ et al., 2016, 2014,
Bourget et al., 2014] have been investigated to control cytotoxic compounding drugs. Despite
their importance in the cancer therapy, only few studies reported on analytical methods to con-
trol mAbs preparations [Bazin et al., 2010, Jaccoulet et al., 2016b,a, 2015, Paul et al., 2012, Ashton
et al., 2013]. All of these techniques were invasive and required a sampling of the preparation for
analysis. Because of the inherent toxicity of cytotoxic drugs as cancerogenic, mutagenic and ter-
atogenic properties, these drugs present a risk of occupational exposure for healthcare workers.
Thus, we decided to explore the feasibility of a noninvasive, nondestructive, and rapid analyti-
cal method as Raman spectroscopy to ensure the quality of the mAbs preparations produced at
hospital. This molecular vibrational spectroscopy based on inelastic scattering of monochromatic
light, usually from a laser in the visible, near infrared, or near ultraviolet range, was successfully
investigated for chemotherapy drug control [Leˆ et al., 2016, 2014, Amin et al., 2014, Bourget et al.,
2014].
Due to the complexity of Raman spectral data, multivariate analysis has to be used to ex-
tract pertinent information. We have tried traditional linear techniques (partial least squares dis-
criminant analysis and regression) and we obtained unsatisfactory results at both the molecule
classification and concentration regression tasks. In this paper we report results using machine
learning methods. We have built an analytics workflow (Figure 1), and submitted the data to
a collaborative data challenge platform called Rapid Analytics and Model Prototyping (RAMP;
http://ramp.studio), developed by the Paris-Saclay Center of Data Science. A large number
of feature extraction and prediction techniques were submitted by about 500 data scientists. The
top results, reported in this paper, were obtained after about five days of collaborative work.
2 Material and methods
2.1 mAbs Samples
We evaluated four mAbs: Bevacizumab (Avastin R© 25 mg/mL from Roche), Infliximab (Remicade R©
100 mg from Schering-Plough), Ramucirumab (Cyramza R© 10 mg/mL from Lilly), and Ritux-
imab (Mabthera R© 10 mg/mL from Roche). We prepared all drugs separately in aseptic condition
and analyzed them after dilution in 0.9% chloride sodium at various concentrations that cover
the therapeutic range currently prepared to treat patients (10 concentrations for each drug: Be-
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Figure 1: The data acquisition and data analytics pipeline.
vacizumab from 0.5 to 25 mg/mL, Infliximab from 0.3 to 10 mg/mL, Ramucirumab from 1 to
10 mg/mL and Rituximab from 0.4 to 10 mg/mL). We prepared 12 independent series (12 batch
of 0.9% chloride sodium) for each drug. We conditioned all compounded solutions into 3 glass
vials (Interchim R©, Montluon, France), conserved at +4 ◦C, and analyzed in accordance to labora-
tory requirements.
Throughout the paper, we will use the following labels for the four drugs: A= Infliximab;
B=Bevacizumab; Q=Ramucirumab, R=Rituximab.
2.2 Raman spectroscopy
We performed Raman spectral acquisitions with a Labram HR evolution microspectrometer (Horiba
Jobin Yvon, Lille, France). The excitation source was a 633 nm single-mode diode laser (Toptica
Photonics, Germany) generating 35 mW on the sample. The microspectrometer was equipped
with an Olympus microscope and measurements were recorded using 10 and 100X MPlan objec-
tives (Olympus, Japan). We collected light scattered by the sample through the same objective.
We intercepted Rayleigh elastic scattering by an edge filter. A Peltier cooled (-70 ◦C) multichan-
nel CCD detector (Coupled Charge Device; 1024 × 256 pixels) detected the Raman Stokes signal
dispersed with a 100 µm slit width and 600 grooves/mm holographic grating. The spectral reso-
lution from the full width at half maximum of the silica wafer band at 521 cm−1 was 2 cm−1. We
studied the spectral region of 400 - 4000 cm−1. The acquisition time of each spectrum was 2× 15 s
per collected spectrum to have better sensitivity. We conducted spectral acquisition and data pre-
processing with Labspec6 software (Horiba Jobin Yvon SAS, Lille, France). Because the sample
compartment was not adapted to analyze vials, we used a homemade vial adaptor to centralize
the vial and to secure the position of the sample on the base plate. In order to correct spectral
variation due to focalization, we pre-treated all Raman spectra using LabSpec6 by normalization
based on total area. The result of this collection step was a spectrum containing 1866 values.
The raw spectra are shown in Figure 2 for all concentrations and all molecules. Raman spectra
of mAbs, similarly to that of other proteins, are very difficult to interpret. Inter and intra molecu-
lar effects including peptide-bond angles and hydrogen-bonding patterns may influence Raman
band positions. Structural information can nevertheless be deduced from Raman vibrational
bands as amide I and amide III bands at 1650 and 1300 cm−1, respectively.
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(a) All spectra (b) Mean spectra per concentration
(c) Mean spectra per molecule
Figure 2: Raw spectra and mean spectra grouped by different axes.
2.3 Data analysis
In this section we formalize the data analysis problem and report overall results using traditional
linear techniques and statistical machine learning approaches. We will present a more detailed
analysis using the optimal technique in Section 3.
The goal of the data analysis is to predict the drug type ` and its concentration y based on the
recorded Raman spectrum s ∈ R1866. We used the following experimental protocol to develop
and tune the analysis techniques and to test and compare the different methods. We collected a
total of 360 spectra for each of the four mAbs agents, except for Ramucirumab (348 spectra). Fol-
lowing the standard machine learning protocol that consists in evaluating model performance
on a held out set of data, the 1428 measurements were randomly split into two data sets. The
429 test instances were used to evaluate the developed techniques. All results reported in this
paper are coming from this test set, but they were hidden from the analysts throughout devel-
opment. The remaining 999 points were further split into eight random cross-validation folds.
Each training and validation set contained 799 and 200 points, respectively. Each technique was
trained eight times on the training sets. The eight trained models were then evaluated on each
validation and test point. The final prediction is the average of these eight predictions on each
validation and test point. This technique, commonly known as cross-validation bootstrap aggre-
gation (CV bagging), takes advantage of the variance reduction property of averaging and allows
us to develop robust predictors despite the small data size. To further improve the results, we
blended the best models using the technique of Caruana et al. [2004]. In a nutshell, we take the
pointwise mean prediction of the best models selected in a greedy loop until the validation result
stops improving.
To allow the analysts to focus on various steps of the data analysis, we split the workflow into
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four modules (Figure 1). The first feature extractor gclf converts the raw spectra s into a fixed
size feature vector xclf = gclf(s). This is then followed by a classifier f clf that outputs a vector
p = (pA, pB, pQ, pR) = f clf
(
xclf
)
, indexed by the four drug types, representing the estimated
probability that the spectrum belongs to each of the four types. The predicted class is then
̂`= arg max
j∈{A, B, Q, R}
pj .
The second feature extractor greg also receives the raw spectra s but also the probability vector c =
f clf(gclf(s)), and converts them into a fixed size feature vector xreg = greg(s, c). The rationale is to
let the regression algorithm know the (estimated) identity of the molecule whose concentration
it has to predict. The final module is a regression model f reg that takes this second feature vector
xreg and estimates the drug concentration
ŷ = f reg
(
xreg
)
.
Given a validation or test set D = {(si, `i, yi)}ni=1 containing triplets of spectra, molecule
types, and concentrations, we evaluate the performance of the modelM = (gclf, f clf, greg, f reg)
as follows. We first compute the classification error
Rclf(M,D) = 1
n
n
∑
i=1
I
{
`i 6= ̂`i} ,
where the indicator function I {X} is one if its argument X is true, and zero otherwise. To assess
the concentration predictor, we use the mean absolute relative error (MARE)
Rreg(M,D) = 1
n
n
∑
i=1
|yi − ŷi|
yi
.
The analysts were instructed to minimize a combined error
Rcomb(M,D) = 2
3
Rclf(M,D) + 1
3
Rreg(M,D) .
The coefficients are reflecting the more stringent requirements posed on the classification task.
2.3.1 The traditional linear approach
To establish baseline performance, we applied linear discrimination and regression methods us-
ing the Matlab software R2011a, common in traditional chemometry. That is to say, both the
preprocessing gclf, greg and the predictor functions f clf, f reg were linear. Classification was per-
formed using partial least squares discriminant analysis (PLS-DA) and principal component anal-
ysis discriminant analysis (PCA-DA). We used PLS regression for estimating the concentration.
Both for classification and regression, we used various spectral processing techniques to limit the
non-informative spectral background: baseline correction with a nth degree polynomial curve,
first and second Savitsky-Golay derivatives, standard normal variate (SNV), and combined pre-
processing. For each model, the optimal number of latent variables was determined by 10-fold
cross validation.
The overall misclassification rate of the baseline method was 14.5% while its MARE was
14.7%. More detailed analysis of the performance can be found in Section 3.
2.3.2 A crowdsourced machine learning approach
Machine learning is essentially a trial-and-error-based science. The scikit-learn library [Pedregosa
et al., 2011], which most of our analysts used, contains dozens of different regression and clas-
sification techniques. Selecting and tuning the best predictor takes experience and a lot of ex-
periments. The choice of feature extractors and filters is even larger. The Paris-Saclay Center for
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Data Science has developed a unique collaborative studio which allows a large number of data
scientists to collaborate on various scientific and industrial data analytics workflows. Partici-
pants have access to a brief description, the public training data set, and a first (non-optimized)
solution in a starting kit. They study the problem, develop and tune solutions, and submit them
through a web interface (Figure 3(a)). The models are then trained and evaluated, and the valida-
tion performance score is fed back to the participants through a public leaderboard (Figure 3(b)).
The test score obtained on the held out test set, reported in this paper, remains hidden from the
participants to avoid overfitting.
(a) The code submission interface (b) The leaderboard
Figure 3: (a) RAMP participants submit models (code) through a web interface and receive feed-
back through the (b) public leaderboard.
Unlike most of the data challenge sites that expect solutions to analytics problems, we ask the
data scientists to submit code. This gives us more flexibility at the evaluation, generates a working
prototype, and, most importantly, lets participants to collaborate by looking at each other’s code
and combining the different ideas. The code is publicly available at the website (after free sign-
up), making the results fully reproducible by anyone. Moreover, any new method can be easily
tested by submitting it on the site, so our results are fully transparent.
The drug spectra challenge was submitted to more than three hundred students in three dif-
ferent classroom RAMPs at Universite´ Paris-Saclay, Ecole Polytechnique, and Mines ParisTech.
Each RAMP involved about five days of work. In each class, we started with a closed period
when students did not see each other’s code, only their scores. This allowed us to grade the
students individually but also to make them explore the space of solutions independently. This
was followed by an open collaborative period. On the other hand, the classes could not see the
solutions developed by the other classes. This, interestingly, led to different collective strategies
in solving the problem. We blended the models in each RAMP separately which made it possible
to compare the collaborative score of each group.
The overall winner of the contest was the Mines RAMP with a classification error of 0.7%
(only three low-concentration test samples were missed!) and a concentration MARE of 5.8%.
The dominant solution that the group converged to was a log transformation of the spectra (but
no other smoothing or preprocessing), followed by either factor analysis or principal compo-
nent analysis to extract 10 features, followed by a small neural network. Interestingly, the same
pipeline worked for both classification and regression, with, of course, different parameteriza-
tions of the neural net. In the regression step, all top models used the same strategy: to learn a
different regression model (although parametrized the same way) for each molecule.
The Saclay RAMP (chronologically the first) achieved a classification error of 1.6% and a con-
centration MARE of 4.9%. This group did more preprocessing. Smoothing of the spectra was
done with linear filters such as the Savitzky–Golay filter [Schafer, 2011] that allows to preserve
the amplitudes of the peaks in the signal. Certain models used simpler strategies based on convo-
lution with Hanning windows. Following the smoothing step, the baseline correction was done
by subtracting a polynomial least square fit of the data or simply by removing a constant. The
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molecule miscl. rate (linear) MARE (linear) miscl. rate (ML) MARE (ML)
Infliximab 13.7% 12.3% 0.9% 8.4%
Bevacizumab 19.8% 14.0% 1.0% 4.3%
Ramucirumab 9.0% 7.3% 0.0% 3.5%
Rituximab 16.0% 26.7% 1.0% 6.9%
Overall 14.5% 14.7% 0.7% 5.8%
Table 1: Misclassification rates and concentration MAREs obtained by the traditional chemomet-
ric (linear) baseline method (Section 2.3.1) and by the crowdsourced machine learning ensemble
(Section 2.3.2) on 429 test points.
polynomial order was 0 (constant) or 1 (linear). The order 0 corresponds to the subtraction of the
mean of the spectra. Some of the solutions proposed to subtract the median of the spectra. As the
machine learning models employed in the second step are sensitive to the scale of the data, the
spectra, for some models, were normalized so that each spectrum after smoothing and baseline
correction was of norm one. For prediction, the majority of winning solutions employed non-
linear kernel-based techniques: kernel PCA for non-linear dimensionality reduction [Scho¨lkopf
et al., 1998] and support vector machines (SVM) for prediction [Cristianini and Shawe-Taylor,
2000]. The best proposed approaches used Gaussian kernels and polynomial kernels of order up
to 4. The low MARE was achieved by exploiting the fact that concentrations were discretized
(see Section 4).
Finally, the Polytechnique RAMP achieved a classification error of 2.1% and a concentration
MARE of 12.2%. The reason of the suboptimal performance was that the group was only ex-
ploring forest-based regression models (extra trees [Geurts et al., 2006], random forests [Breiman,
2001], gradient boosting [Friedman, 2000]). These otherwise popular and usually well-performing
nonparametric classifiers seemed to be a suboptimal choice for the functional data we had in this
problem.
Note again that all the models and code are available freely at the RAMP site, so anybody
can consult their detailed parameterizations, reuse them, and reproduce the results. Further-
more, anybody can resubmit competing solutions which will be tested using the same protocol
as during the RAMPs, on the same training and test sets.
3 Results
Table 1 shows that the large improvement obtained by machine learning techniques is uniform
across all molecules. The three misclassified molecules (that correspond to the overall misclassi-
fication rate of 0.7%) all came from samples with low concentration (y ≤ 0.6 mg/ml). Using the
linear method, 63% of the samples below concentration y ≤ 1 mg/ml had larger relative error
than 15% whereas the figure was only 5.6% in the case of the ML method.
Figure 5 shows the estimation bias (the mean of the relative error (y− ŷ)/y) and the resolu-
tion (the standard deviation of the relative error) as a function of the concentration. Besides a
downward slope explained by regression to the mean, the bias (Figure 5(a)) is negligible above
0.1 mg/ml. The relative resolution (Figure 5(b)) drops sharply with the concentration (not sur-
prisingly) from 15% (below y < 1 mg/ml) to 5% (above y > 3 mg/ml).
4 Discussion
Over the last decade, the interest of statistical machine learning for biological applications has
grown considerably. As part of both computer science and statistics, machine learning (ML), as a
scientific discipline, aims to develop algorithms that can make sense of data. A typical outcome
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Figure 4: True and predicted concentrations for each molecule. Predictions are obtained with
the ensemble model of the Mines RAMP.
(a) Bias of the concentration estimate (b) Resolution of the concentration estimate
Figure 5: The relative bias and resolution of the ML concentration estimate as a function of the
concentration. Error bars are one standard deviation.
of machine learning is a model that can make prediction from new data, after having learnt
from many training examples. Based on the hypothesis that spectra are influenced by the nature
and the concentration of mAbs in solution, we decided to explore how machine learning can
help to resolve the pharmaceutical challenge of classification and concentration estimation for
pharmaceutical drugs particularly difficult to discriminate by traditional analytical methods.
We found that combining Raman spectroscopy with machine learning methods present an
interesting potential to secure the medication process by the identification and the quantification
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of chemotherapy preparations.
As opposed to traditional analysis using CLHP/UV or LC/MS/MS, Raman spectroscopies,
such as near infrared spectroscopy, allow direct measurement through the glass and plastic pack-
aging Broad et al. [2000], Vergote et al. [2002]. Because of rapid analysis and non-destructive
and non-invasive measurements, those spectroscopies are largely used for the Process Analyt-
ical Technology De et al. [2011] with at-line and on-line measurements to control primary and
secondary manufacturing process in the pharmaceutical industry.
Despite promising results to ensure the nature and the dose of the drug in solution by clas-
sification and regression analysis respectively, machine learning has some particular limitations
and pitfalls that should be avoided. Machine learning algorithms usually require more train-
ing data to train than linear models. In addition, one has to be careful to collect data under the
same distribution as when the predictors are used in practice. First, if the training concentra-
tions are over- or under-sampled in certain regions, the nonparametric concentration estimate
may be biased towards the oversampled values. This is due to the fact that machine learning
models try to minimize the errors on average. Second, if only certain concentration levels are
used for certain molecules, the classifier can learn these values and use the concentration infor-
mation for classification. Third, if the concentration levels are discretized, the regression model
can learn those discretization levels, and quantize the continuous estimate, creating a bias in case
true concentrations fall between those levels. In fact, one of the student groups boosted the pre-
diction accuracy by forcing the model to predict only concentrations present in the training set.
More concretely, they rounded the predicted concentration by a regression model to the closest
discrete concentration. In our study, the predictors were so precise that these effects were neg-
ligible, but in more complicated measurements, with larger uncertainties, they have to be taken
into consideration. One practical way to consider in future data collection protocols in order to
prevent performance gains by rounding is to randomize concentration values using a sampling
distribution that matches realistic scenarios.
5 Conclusion
Due to similar structures and low concentration values, discrimination and quantification of
mAbs preparations posed difficult challenges. In addition to the type of analytical technique,
this study have highlighted the importance of the data analysis method and more particularly
the power of statistical machine learning associated to Raman spectroscopy to ensure the chemi-
cal quality of medications produced at hospital before patient administration.
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